EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Photobiomodulation to minimize talquetamab-associated dysgeusia and xerostomia in multiple myeloma: a brief report of four cases

Mariana Henriques Ferreira, Fernanda de Paula Eduardo, Luiza Deitos Menti, Isabela Vieira Nasser de Morais, Nelson Hamerschlak, Mariana Nassif Kerbauy, Gabriela Rocco de Sá, Letícia Mello Bezinelli

Supportive Care in Cancer · 2026-09 · 34 (9)

DOI: 10.1007/s00520-026-11133-8 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Supportive Care in Cancer, online erschienen am 22.08.2026. Verfasst von Mariana Henriques Ferreira und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Israelita Albert Einstein, São Paulo, Brazil. Hauptthemen laut MEDLINE: Antineoplastic Agents, Dysgeusia, Low-Level Light Therapy, Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculdade Israelita De Ciências Da Saúde Albert Einstein.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Talquetamab, a GPRC5D-targeting bispecific antibody, produces high response rates in relapsed/refractory multiple myeloma (RRMM) but is frequently associated with oral adverse effects, most commonly dysgeusia and xerostomia, which can impair nutrition and quality of life. No evidence-based supportive-care intervention has been established for these effects.

Methods

We describe four adults with RRMM who received photobiomodulation (PBM) concomitantly with talquetamab, using a dual-wavelength (660/808 nm) protocol individualized to symptom evolution and patient availability. Dysgeusia and xerostomia were assessed prospectively at each session through structured clinical interview and oral examination, with severity graded for each patient; no formal psychophysical gustatory testing or sialometry was performed. This descriptive, uncontrolled case series was designed to report the feasibility and tolerability of PBM rather than its efficacy.

Results

All four patients developed dysgeusia during talquetamab treatment. Two had grade 1, intermittent hypogeusia; two had grade 2 dysgeusia with complete taste loss (ageusia). No patient developed oral mucositis or clinically significant oral pain. All four patients reported xerostomia, with reduced salivary film and whitish, viscous saliva on examination; salivary flow was not measured quantitatively. All patients also received xylitol-based mouthwash and saliva substitutes from the start of talquetamab as concomitant standard supportive care. PBM was well tolerated, with no PBM-related adverse events, and no patient discontinued talquetamab because of oral toxicity.

Conclusions

This series demonstrates the feasibility and tolerability of PBM delivered alongside talquetamab in four patients. Given the small, uncontrolled sample and concurrent supportive interventions, no conclusion can be drawn regarding the efficacy of PBM for talquetamab-associated dysgeusia or xerostomia. Controlled studies with objective, validated outcome measures are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDysgeusiaLow-Level Light TherapyMultiple MyelomaXerostomiaAgedFemaleHumansMiddle AgedFeasibility StudiesAged, 80 and overAntibodies, Bispecific

Stichwörter der Autor:innen

DysgeusiaMultiple myelomaPhotobiomodulationSupportive careTalquetamabXerostomia

Substanzen

Antineoplastic AgentstalquetamabAntibodies, Bispecific

Autor:innen und Institutionen

  • Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Hospital Israelita Albert Einstein, São Paulo, Brazil. fpeduard@einstein.br.
  • Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, Brazil. fpeduard@einstein.br.
  • Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, Brazil.

Förderung

  • Faculdade Israelita De Ciências Da Saúde Albert Einstein

Zitieren

APA

Ferreira, M. H., de Paula Eduardo, F., Menti, L. D., de Morais, I. V. N., Hamerschlak, N., Kerbauy, M. N., de Sá, G. R., & Bezinelli, L. M. (2026). Photobiomodulation to minimize talquetamab-associated dysgeusia and xerostomia in multiple myeloma: a brief report of four cases. Supportive Care in Cancer, 34(9). https://doi.org/10.1007/s00520-026-11133-8

Vancouver

Ferreira MH, de Paula Eduardo F, Menti LD, de Morais IVN, Hamerschlak N, Kerbauy MN, et al. Photobiomodulation to minimize talquetamab-associated dysgeusia and xerostomia in multiple myeloma: a brief report of four cases. Supportive Care in Cancer. 2026;34(9). doi:10.1007/s00520-026-11133-8

BibTeX
@article{Ferreira2026,
  author = {Ferreira, Mariana Henriques and de Paula Eduardo, Fernanda and Menti, Luiza Deitos and de Morais, Isabela Vieira Nasser and Hamerschlak, Nelson and Kerbauy, Mariana Nassif and de Sá, Gabriela Rocco and Bezinelli, Letícia Mello},
  title = {Photobiomodulation to minimize talquetamab-associated dysgeusia and xerostomia in multiple myeloma: a brief report of four cases},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {9},
  doi = {10.1007/s00520-026-11133-8}
}
Kostenlos starten →